Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use

Details for Australian Patent Application No. 2005269995 (hide)

International Classifications

Event Publications

23 August 2007 Section 223 Application Received

Zymogenetics, Inc. An application to extend the time from 06 Feb 2007 to 06 Jul 2007 in which to enter the national phase has been filed. . Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

18 October 2007 Section 223 Application Allowed

Zymogenetics, Inc. The time in which to enter the national phase has been extended to 06 Jul 2007. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

25 October 2007 PCT application entered the National Phase

PCT publication WO2006/014444 Priority application(s): WO2006/014444

20 January 2011 Application Accepted

Published as AU-B-2005269995

19 May 2011 Standard Patent Sealed

14 July 2011 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 20 May 2011. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

1 December 2011 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 20 May 2011

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.